BioSpace News Archive

InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Robert J. Rosenthal, Ph.D., to the Company’s Board of Directors, effective November 8, 2019.

The exchange is expected to close on November 14, 2019, subject to customary closing conditions.

Landmark Agreement with Sumitomo Dainippon Pharma to provide major financial backing and safeguards for minority shareholders

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced positive initial data from an acute, dose escalation, clinical study (PHPF-002) of INOpulse® for the treatment of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)

KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Thursday, November 14, 2019, at 5:30 p.m. ET, to discuss its corporate and financial results for the third quarter 2019.

Funding expected to extend Company’s cash runway into 2021, well past its expected topline data readouts for global Phase 3 studies for vadadustat;

Today in Nature Medicine, researchers from Barts Cancer Institute (London), Queen Mary University of London together with pathologists from HistoGeneX (Belgium), a laboratory focused on tissue pathology and genomics, published findings that may significantly alter the treatment of bladder cancer

Double-blind, placebo-controlled trial evaluating FDY-5301 for treatment of reperfusion injury following heart attack [12-November-2019] SEATTLE , Nov. 12, 2019 /PRNewswire/ -- Faraday Pharmaceuticals, a biopharmaceutical company focused on the development of elemental reducing agents for critical care medicine, today announced that top-line results from its Phase 2 t

NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today reported FDA authorization of Omics Core℠, the first whole exome tumor-normal in vitro diagnostic (IVD) that measures overall tumor mutational burden (TMB) in cancer tissue.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the following healthcare investor conferences in November: